Stockscreener 앱 받기
1.525
4.09%
-0.065
전일 마감가:
$1.59
열려 있는:
$1.59
하루 거래량:
969.39K
Relative Volume:
0.93
시가총액:
$256.87M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-1.6576
EPS:
-0.92
순현금흐름:
$-84.71M
1주 성능:
+11.31%
1개월 성능:
+27.08%
6개월 성능:
-9.23%
1년 성능:
+42.52%
1일 변동 폭
$1.51
$1.60
1주일 범위
$1.43
$1.95
52주 변동 폭
$1.025
$2.85
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ATAI | 1.525 | 256.87M | 314.00K | -40.23M | -84.71M | -0.92 |
| VRTX | 449.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.51 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.60 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan
374Water And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Are ATAI Life Sciences N.V.’shares a good deal? - US Post News
Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s results reveal risk - US Post News
Maxim Group gives a Buy recommendation for ATAI Life Sciences N.V. (ATAI) - Knox Daily
ATAI Life Sciences completes acquisition of IntelGenx Corp. - Investing.com India
ATAI Life Sciences completes acquisition of IntelGenx Corp. By Investing.com - Investing.com South Africa
10% Owner ATAI Life Sciences N.V. sale 2,660,000 shares of ATAI Life Sciences N.V. [ATAI] - Knox Daily
ATAI Life Sciences N.V. (ATAI) stock analysis: A comprehensive overview - US Post News
Trading Day Review: ATAI Life Sciences N.V. (ATAI) Loses Momentum, Closing at 1.16 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: ATAI Life Sciences N.V. (ATAI) - SETE News
Maxim Group Upgrades ATAI Life Sciences N.V. (ATAI) to a Buy from a Hold - Knox Daily
Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock - MarketBeat
Atai Life Sciences executives sell shares valued at $16 million - Investing.com India
Deeper Dive: Understanding ATAI Life Sciences N.V. (ATAI) Through its Various Ratios - The Dwinnex
ATAI Life Sciences N.V. (ATAI) deserves closer scrutiny - US Post News
ATAI Life Sciences N.V. [ATAI] Shares Fall Approximately -7.81% Over the Year - Knox Daily
TWKS SPECIAL ALERT: Thoughtworks Shareholders Seeking More Than $4.40 Per Share Contact Julie & Holleman Regarding Sale to Apax - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
T2 Biosystems Achieves Successful Defense of Patent for - GlobeNewswire
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
ATAT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Australian Clinical Labs Shareholder Stake Shifts - TipRanks
(ATAT) Trading Advice - Stock Traders Daily
T2 Biosystems director sells shares worth $133 - Investing.com India
Atour Lifestyle Holdings Ltd ADR (ATAT) is looking forward to a strong quarter - SETE News
Atour Lifestyle Holdings Limited (NASDAQ:ATAT) Short Interest Down 8.3% in August - MarketBeat
Alzheimer’s drug developer Actinogen rattles the tin - The Australian Financial Review
Substantial Stake Acquired in Australian Clinical Labs - TipRanks
Cat defies the odds to survive after being born with two faces - MSN
ATAI Life Sciences N.V. [ATAI] See Remarks makes an insider sale of 151,303 shares worth $0.29 million. - Knox Daily
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients - GlobeNewswire
Two-faced kitten in Phetchabun leaves locals feline lottery curious - Thaiger
Monitoring ATAI Life Sciences N.V. (ATAI) after recent insider movements - Knox Daily
Market Watch Highlights: ATAI Life Sciences N.V. (ATAI) Ends on an Upturn Note at 1.24 - The Dwinnex
ATAI Life Sciences N.V. [ATAI] Insider Activity: An Update for Investors - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s stock chart: A technical perspective - US Post News
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Psychedelic Stock Deep Dive: Atai Life Sciences (ATAI) (NASDAQ:ATAI) - Seeking Alpha
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):